A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
VERITAC-2
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)
2 other identifiers
interventional
624
30 countries
310
Brief Summary
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Mar 2023
Longer than P75 for phase_3
310 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 16, 2022
CompletedFirst Posted
Study publicly available on registry
December 16, 2022
CompletedStudy Start
First participant enrolled
March 3, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 31, 2025
CompletedResults Posted
Study results publicly available
February 3, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 15, 2028
ExpectedMarch 18, 2026
February 1, 2026
1.9 years
November 16, 2022
January 15, 2026
February 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants
PFS assessed by BICR was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) per RECIST v1.1, or death due to any cause, whichever occurred first. PD as per RECIST v1.1 was defined as at least a 20% increase in the sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to the timepoint under evaluation), with a minimum absolute increase of 5 millimeters (mm) relative to nadir or unequivocal progression of existing non-target lesions or the presence of new lesions. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method was used.
From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation
PFS assessed by BICR was defined as the time from the date of randomization to the date of the first documentation of objective PD per RECIST v1.1, or death due to any cause, whichever occurred first. PD as per RECIST v1.1 was defined as at least a 20% increase in the sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to the timepoint under evaluation), with a minimum absolute increase of 5 mm relative to nadir or unequivocal progression of existing non-target lesions or the presence of new lesions. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method was used.
From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Secondary Outcomes (16)
Overall Survival (OS)-All Randomized Participants
From date of randomization to the date of death due to any cause or censoring date
OS-Participants With ESR1 Mutation
From date of randomization to the date of death due to any cause or censoring date
Percentage of Participants With Objective Response (OR) by BICR Assessment- Participants With Measurable Disease at Baseline
From randomization until PD, death or start of new anticancer therapy, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Clinical Benefit Rate (CBR) by BICR Assessment
From randomization until PD, death due to any cause or start of new anticancer therapy, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Duration of Response (DOR) by BICR Assessment
From first documentation of objective tumor response until confirmed PD or death, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
- +11 more secondary outcomes
Study Arms (2)
ARV-471
EXPERIMENTALFulvestrant
ACTIVE COMPARATORInterventions
orally, once daily on a 28-day continuous dosing schedule
intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)
Eligibility Criteria
You may qualify if:
- Adult participants with loco-regional recurrent or metastatic breast disease not amenable to surgical resection or radiation therapy
- Confirmed diagnosis of ER+/HER2- breast cancer
- Prior therapies for locoregional recurrent or metastatic disease must fulfill all the following criteria:
- One line of CDK4/6 inhibitor therapy in combination with endocrine therapy. Only one line of CDK4/6 inhibitor is allowed in any setting.
- ≤ 1 endocrine therapy in addition to CDK4/6 inhibitor with ET
- Most recent endocrine treatment duration must have been given for ≥6 months prior to disease progression. This may be the endocrine treatment component of the CDK4/6 inhibitor line of therapy.
- Radiological progression during or after the last line of therapy.
- Measurable disease evaluable per Response Evaluation Criterion in Solid Tumors (RECIST) v.1.1 or non-measurable bone-only disease
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Participants should be willing to provide blood and tumor tissue
You may not qualify if:
- Participants with advanced, symptomatic visceral spread, that are at risk of life-threatening complications in the short term
- Prior treatment with:
- ARV-471, fulvestrant, elacestrant, mTOR, PI3K, AKT pathway inhibitors, PARP inhibitor for any setting
- other investigational agents (including novel endocrine therapy any SERDs, SERCAs, CERANs) for any setting
- prior chemotherapy for advanced/metastatic disease
- Inadequate liver, kidney and bone marrow function
- Active brain metastases
- Participants with significant concomitant illness
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
- Arvinas Estrogen Receptor, Inc.collaborator
Study Sites (312)
California Cancer Associates for Research and Excellence, Inc. (cCARE)
Encinitas, California, 92024, United States
Orange Coast Memorial Medical Center
Fountain Valley, California, 92708, United States
California Cancer Associates for Research and Excellence
Fresno, California, 93720, United States
Providence Queen of the Valley Medical Center
Napa, California, 94558, United States
California Cancer Associates for Research and Excellence
San Marcos, California, 92069, United States
Olive View-UCLA Medical Center
Sylmar, California, 91342, United States
Smilow Cancer Hospital Care Center at Fairfield
Fairfield, Connecticut, 06824, United States
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut, 06510, United States
Yale-New Haven Hospital
New Haven, Connecticut, 06510, United States
Smilow Cancer Hospital Care Center at North Haven
North Haven, Connecticut, 06473, United States
Smilow Cancer Hospital Care Center at Trumbull
Trumbull, Connecticut, 06611, United States
Florida Cancer Specialists
Altamonte Springs, Florida, 32701, United States
Florida Cancer Specialists BON
Bonita Springs, Florida, 34135, United States
Florida Cancer Specialists BCC
Bradenton, Florida, 34205, United States
Florida Cancer Specialists LRS
Bradenton, Florida, 34211, United States
Florida Cancer Specialists
Brandon, Florida, 33511, United States
Florida Cancer Specialists NFM
Cape Coral, Florida, 33909, United States
Morton Plant Hospital - BayCare Health System
Clearwater, Florida, 33756, United States
Florida Cancer Specialists
Clearwater, Florida, 33761, United States
Florida Cancer Specialists
Daytona Beach, Florida, 32117, United States
Florida Cancer Specialists COL
Fort Myers, Florida, 33905, United States
Florida Cancer Specialists GLO
Fort Myers, Florida, 33908, United States
Florida Cancer Specialists
Gainesville, Florida, 32605, United States
Lakeland Regional Cancer Center
Lakeland, Florida, 33805, United States
Florida Cancer Specialists
Largo, Florida, 33770, United States
Florida Cancer Specialists
Lecanto, Florida, 34461, United States
Florida Cancer Specialist And Research Institute
N. Venice, Florida, 34275, United States
Florida Cancer Specialists NGD
Naples, Florida, 34102, United States
Florida Cnacer Specialists
North Port, Florida, 34286, United States
Florida Cancer Specialists
Ocala, Florida, 34474, United States
Florida Cancer Specialists
Orange City, Florida, 32763, United States
Florida Cancer Specialists
Orlando, Florida, 32806, United States
Florida Cancer Specialists PCH
Port Charlotte, Florida, 33980, United States
Florida Cancer Specialists SAC
Sarasota, Florida, 34232, United States
Florida Cancer Specialists SAD
Sarasota, Florida, 34236, United States
Florida Cancer Specialists
St. Petersburg, Florida, 33705, United States
Florida Cancer Specialists
Stuart, Florida, 34994, United States
Florida Cancer Specialists
Tampa, Florida, 33607, United States
Florida Cancer Specialists
Tavares, Florida, 32778, United States
Florida Cancer Specialists
The Villages, Florida, 32159, United States
Florida Cancer Specialist
Trinity, Florida, 34655, United States
Florida Cancer Specialists
Vero Beach, Florida, 32960, United States
Florida Cancer Specialists
Wellington, Florida, 33414, United States
Florida Cancer Specialists
West Palm Beach, Florida, 33401, United States
Florida Cancer Specialists
Winter Park, Florida, 32789, United States
Hope and Healing Cancer Services
Hinsdale, Illinois, 60521, United States
Norton Cancer Institute - Downtown
Louisville, Kentucky, 40202, United States
Norton Cancer Institute, Downtown
Louisville, Kentucky, 40202, United States
Norton Hospital
Louisville, Kentucky, 40202, United States
Norton Cancer Institute, St Matthews Campus
Louisville, Kentucky, 40207, United States
Norton Women's & Children's Hospital
Louisville, Kentucky, 40207, United States
Norton Brownsboro Hospital
Louisville, Kentucky, 40241, United States
Norton Cancer Institute, Brownsboro Hospital Campus
Louisville, Kentucky, 40241, United States
University Medical Center New Orleans
New Orleans, Louisiana, 70112, United States
Louisiana State University Health Sciences Shreveport
Shreveport, Louisiana, 71103, United States
Hattiesburg Clinic Hematology/Oncology
Hattiesburg, Mississippi, 39401, United States
Mercy Clinic Oncology and Hematology
Ballwin, Missouri, 63011, United States
Saint Luke's Cancer Institute
Kansas City, Missouri, 64111, United States
Mercy Research - David C. Pratt Cancer Center
St Louis, Missouri, 63141, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
MSK Basking Ridge
Basking Ridge, New Jersey, 07920, United States
MSK Monmouth
Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering - Bergen
Montvale, New Jersey, 07645, United States
Hematology Oncology Associates of CNY
Camillus, New York, 13031, United States
MSK Commack
Commack, New York, 11725, United States
Hematology-Oncology Associates of Central New York, PC
East Syracuse, New York, 13057, United States
MSK Westchester
Harrison, New York, 10604, United States
R.J. Zuckerberg Cancer Center
Lake Success, New York, 11042, United States
Northern Westchester Hospital
Mount Kisco, New York, 10549, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
MSK Evelyn H. Lauder Breast and Imaging Center
New York, New York, 10065, United States
Hematology Oncology Associates of Rockland
Nyack, New York, 10960, United States
Phelps Hospital
Sleepy Hollow, New York, 10591, United States
MSK Nassau
Uniondale, New York, 11553, United States
Cancer Centers of Southwest Oklahoma
Lawton, Oklahoma, 73505, United States
Providence Cancer Institute Franz Clinic
Portland, Oregon, 97213, United States
Providence Portland Medical Center
Portland, Oregon, 97213, United States
University of Virginia Cancer Center
Charlottesville, Virginia, 22903, United States
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
UVA Breast Care Center
Charlottesville, Virginia, 22911, United States
Bon Secours Memorial Regional Medical Center
Mechanicsville, Virginia, 23116, United States
Bon Secours St. Francis Medical Center
Midlothian, Virginia, 23114, United States
Bon Secours St. Mary's Hospital
Richmond, Virginia, 23226, United States
Providence Regional Cancer System - Aberdeen
Aberdeen, Washington, 98520, United States
Providence Regional Cancer System- Centralia
Centralia, Washington, 98531, United States
Providence Regional Cancer System - Lacey
Lacey, Washington, 98503, United States
UW Medicine Valley Medical Center
Renton, Washington, 98055, United States
Centro de Oncología e Investigación de Buenos Aires
Berazategui, Buenos Aires, B1884BBF, Argentina
Instituto de Oncología Angel H. Roffo
CABA, Buenos Aires, 1417, Argentina
Stat Research S.A.
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1023AAB, Argentina
Fundación Cenit Para La Investigación En Neurociencias
CABA, Buenos Aires F.D., 1125, Argentina
Fundacion Estudios Clinicos
Rosario, Santa Fe Province, 2000, Argentina
Sanatorio de La Mujer
Rosario, Santa Fe Province, S2000ORE, Argentina
Centro Oncologico Korben
Buenos Aires, 1426, Argentina
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC)
Buenos Aires, 1431, Argentina
Fundación Respirar
Buenos Aires, C1426ABP, Argentina
Clínica Universitaria Reina Fabiola
Córdoba, X5004FHP, Argentina
Coffs Harbour Health Campus
Coffs Harbour, New South Wales, 2450, Australia
Sunshine Coast University Private Hospital
Birtinya, Queensland, 4575, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
ICON Cancer Centre - Kurralta Park
Kurralta Park, South Australia, 5037, Australia
Icon Cancer Centre Hobart
Hobart, Tasmania, 7000, Australia
Cabrini Hospital -Brighton
Brighton, Victoria, 3186, Australia
Barwon Health
Geelong, Victoria, 3220, Australia
Cabrini Hospital - Malvern
Malvern, Victoria, 3144, Australia
Medizinische Universität Graz
Graz, Styria, 8036, Austria
Uniklinikum Salzburg
Salzburg, 5020, Austria
Antwerp University Hospital
Edegem, Antwerpen, 2650, Belgium
Cliniques universitaires Saint-Luc
Woluwe-Saint-Lambert, Bruxelles-capitale, Région de, 1200, Belgium
Grand Hôpital de Charleroi
Gilly, Hainaut, 6060, Belgium
UZ Leuven
Leuven, Vlaams-brabant, 3000, Belgium
Clinical Chc Montlégia
Liège, 4000, Belgium
Hospital Santa Rita de Cassia
Vitória, Espírito Santo, 29043-260, Brazil
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
Ijuí, Rio Grande do Sul, 98700-000, Brazil
Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa
Porto Alegre, Rio Grande do Sul, 90110-270, Brazil
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, 90560032, Brazil
Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
Centro de Pesquisa Clínica - Área Administrativa
Porto Alegre, Rio Grande do Sul, 90850-170, Brazil
Hospital Mae de Deus
Porto Alegre, Rio Grande do Sul, 90880-480, Brazil
ANIMI - Unidade de Tratamento Oncologico
Lages, Santa Catarina, 88501001, Brazil
Faculdade de Medicina do ABC
Santo André, São Paulo, 09060-650, Brazil
A. C. Camargo Cancer Center
São Paulo, São Paulo, 01509-010, Brazil
IBCC - Instituto Brasileiro de Controle do Câncer
São Paulo, 03102002, Brazil
IBCC - Núcleo de Pesquisa e Ensino
São Paulo, 04014-002, Brazil
Complex Oncology Center - Burgas
Burgas, 8000, Bulgaria
Complex Oncology Center - Plovdiv EOOD
Plovdiv, 4004, Bulgaria
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
BC Cancer Surrey
Surrey, British Columbia, V3V 1Z2, Canada
The Moncton Hospital
Moncton, New Brunswick, E1C 6Z8, Canada
Waterloo Regional Health Network
Kitchener, Ontario, N2G 1G3, Canada
Sunnybrook Research Institute
Toronto, Ontario, M4N 3M5, Canada
Unity Health Toronto, St. Michael's Hospital
Toronto, Ontario, M5B 1W8, Canada
Centre de Services Ambulatoires de St-Jerome
Saint-Jérôme, Quebec, J7Y 0L1, Canada
Unité de Recherche Clinique du CISSS des Laurentides
Saint-Jérôme, Quebec, J7Z 2V4, Canada
Anhui Provincial Hospital
Hefei, Anhui, 230001, China
Anhui Provincial Cancer Hospital
Hefei, Anhui, 230031, China
Beijing Hospital
Beijing, Beijing Municipality, 100005, China
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, 100021, China
Fujian Medical University Union Hospital
Fuzhou Fujian, Fujian, 350001, China
The First People's Hospital of Foshan
Foshan, Guangdong, 528041, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510555, China
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, 530201, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, Henan, 471003, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
Wuhan Union Hospital Cancer Center
Wuhan, Hubei, 430022, China
Jinyinhu Branch of Tongji Medical College Affiliated Union Hospital, Huazhong University of Science
Wuhan, Hubei, 430040, China
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210031, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
Nanchang People's Hospital
Nanchang, Jiangxi, 330009, China
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
The 2nd Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, 116023, China
The First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
Liaoning Cancer Hospital
Shenyang, Liaoning, 110042, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710004, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
Yunnan Province Cancer Hospital
Kunming, Yunnan, 650106, China
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
The Second Affiliated hospital of Zhejiang University school of medicine
Hangzhou, Zhejiang, 310052, China
Henan Cancer Hospital
Zhengzhou, 450008, China
Fakultní nemocnice Brno Bohunice
Brno, Brno-město, 625 00, Czechia
Fakultni Thomayerova nemocnice
Prague, Praha 4, 14059, Czechia
Fakultni nemocnice Kralovske Vinohrady
Prague, 10034, Czechia
Tampereen yliopistollinen sairaala
Tampere, Pirkanmaa, 33520, Finland
Vaasan Keskussairaala
Vaasa, Pohjanmaa, 65130, Finland
Satakunnan Keskussairaala
Pori, 28500, Finland
Centre Georges François Leclerc
Dijon, Côte-d'or, 21079, France
Centre de Cancérologie du Grand Montpellier
Montpellier, Languedoc-roussillon, 34070, France
Institut de Cancérologie de l'Ouest
Saint-Herblain, Loire-atlantique, 44805, France
Institut de Cancérologie de l'Ouest
Angers, Maine-et-loire, 49055, France
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne
Clermont-Ferrand, Puy-de-dôme, 63011, France
Sainte Catherine Institut du Cancer Avignon Provence
Avignon, Vaucluse, 84918, France
Centre Hospitalier Universitaire de Poitiers
Poitiers, Vienne, 86021, France
Henri Mondor Hospital
Créteil, Île-de-France Region, 94000, France
Onkologische Schwerpunktpraxis Kurfuerstendamm
Berlin, 10707, Germany
University Hospital of Patras
Pátrai, Achaḯa, 26504, Greece
Alexandra General Hospital of Athens
Athens, Attikí, 115 28, Greece
Attikon General University Hospital
Chaidari/Athens, Attikí, 12462, Greece
University General Hospital of Heraklion
Heraklion, Irakleío, 715 00, Greece
University General Hospital of Larissa
Larissa, Thessalía, 41110, Greece
Petz Aladar Egyetemi Oktato Korhaz
Győr, Győr-Moson-Sopron, 9024, Hungary
Budapesti Uzsoki Utcai Kórház
Budapest, 1145, Hungary
Artemis hospital
Gurgaon, Haryana, 122001, India
Tata Memorial Hospital
Mumbai, Maharashtra, 400012, India
HCG Manavata Cancer Centre
Nashik, Maharashtra, 422002, India
Apex Wellness Hospital
Nashik, Maharashtra, 422009, India
Bhakti Vedanta Hospital and Research Institute
Thane, Maharashtra, 401107, India
Venkateshwar Hospital
New Delhi, National Capital Territory of Delhi, 110075, India
Rajiv Gandhi Cancer Institute And Research Centre
New Delhi, National Capital Territory of Delhi, 110085, India
Institute of Post Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital
Kolkata, West Bengal, 700020, India
Rabin Medical Center
Petah Tikva, Central District, 4941492, Israel
Kaplan Medical Center
Rehovot, Central District, 7610001, Israel
Istituto Nazionale Tumori IRCCS Fondazione Pascale
Naples, Campania, 80131, Italy
Humanitas Istituto Clinico Catanese
Misterbianco, Catania, 95045, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
Bologna, Emilia-Romagna, 40138, Italy
Azienda Ospedaliero Universitaria di Ferrara
Cona, Ferrara, 44124, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
Rome, Lazio, 00168, Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, Lombardy, 20900, Italy
Azienda Ospedaliero Universitaria delle Marche
Ancona, The Marches, 60126, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Tuscany, 56126, Italy
Ospedale Generale Provinciale Macerata
Macerata, 62100, Italy
Istituto Europeo di Oncologia IRCCS
Milan, 20141, Italy
Istituto Oncologico Veneto IRCCS
Padua, 35128, Italy
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, 464-8681, Japan
Nagoya University Hospital
Nagoya, Aichi-ken, 466-8560, Japan
Nagoya City University Hospital
Nagoya, Aichi-ken, 467-8602, Japan
Chiba cancer center
Chiba, Chiba, 260-8717, Japan
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
National Hospital Organization Hokkaido Cancer Center
Sapporo, Hokkaido, 003-0804, Japan
Kanagawa cancer center
Yokohama, Kanagawa, 2418515, Japan
Osaka University Hospital
Suita, Osaka, 565-0871, Japan
Saitama Prefectural Cancer Center
Ina-machi, Saitama, 362-0806, Japan
Juntendo University Hospital
Bunkyo-ku, Tokyo, 113-8431, Japan
Tokyo Metropolitan Komagome Hospital, Department of Breast Surgery
Bunkyo-ku, Tokyo, 113-8677, Japan
Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, 135-8550, Japan
Japanese Foundation for Cancer Research
Koto, Tokyo, 135-8550, Japan
National Center for Global Health and Medicine
Shinjuku, Tokyo, 162-8655, Japan
Center Hospital of the National Center for Global Health and Medicine
Shinjuku-ku, Tokyo, 162-8655, Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, 811-1395, Japan
Sagara Hospital
Kagoshima, 892-0833, Japan
Okayama University Hospital
Okayama, 700-8558, Japan
Boca Clinical Trials Mexico S.C.
Guadajalara, Jalisco, 44600, Mexico
Cryptex Investigación Clínica S.A. de C.V.
Cuauhtémoc, Mexico City, 06100, Mexico
Centro de Investigacion Clinica de Oaxaca
Oaxaca City, 68020, Mexico
Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
Krakow, Lesser Poland Voivodeship, 30-348, Poland
SP ZOZ Szpital Uniwersytecki w Krakowie
Krakow, Lesser Poland Voivodeship, 31-501, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
Warsaw, Masovian Voivodeship, 02-781, Poland
COPERNICUS PL, Wojewodzkie Centrum Onkologii
Gdansk, Pomeranian Voivodeship, 80-219, Poland
Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna
Lodz, Łódź Voivodeship, 90-338, Poland
Puerto Rico Medical Research Center
Hato Rey, Puerto RICO, 00917, Puerto Rico
Hospital Oncológico Dr. Isaac González-Martinez
Rio Piedras, 00935, Puerto Rico
Pan American Center for Oncology Trials, LLC
Rio Piedras, 00935, Puerto Rico
FDI Clinical Research
San Juan, 00927, Puerto Rico
Onkologicky ustav sv. Alzbety, s.r.o.
Bratislava, 812 50, Slovakia
Narodny onkologicky ustav
Bratislava, 833 10, Slovakia
Vychodoslovensky onkologicky ustav, a.s.
Košice, 04191, Slovakia
Nemocnica na okraji mesta n o
Partizánske, 95801, Slovakia
Fakultna nemocnica Trnava
Trnava, 917 75, Slovakia
Iatros International
Bloemfontein, Free State, 9301, South Africa
Charlotte Maxeke Johannesburg Academic Hospital
Johannesburg, Gauteng, 2193, South Africa
WCR Office
Johannesburg, Gauteng, 2193, South Africa
Wits Clinical Research
Johannesburg, Gauteng, 2193, South Africa
Gachon University Gil Medical Center
Namdong-gu, Incheon-gwangyeoksi [incheon], 21565, South Korea
National Cancer Center
Goyang-si, Kyǒnggi-do, 10408, South Korea
Seoul National University Bundang Hospital
Seongnam, Kyǒnggi-do, 13620, South Korea
Ajou University Hospital
Suwon, Kyǒnggi-do, 16499, South Korea
Korea University Anam Hospital
Seoul, Seoul-teukbyeolsi [seoul], 02841, South Korea
Seoul National University Hospital
Seoul, Seoul-teukbyeolsi [seoul], 03080, South Korea
Severance Hospital, Yonsei University Health System
Seoul, Seoul-teukbyeolsi [seoul], 03722, South Korea
Asan Medical Center
Seoul, Seoul-teukbyeolsi [seoul], 05505, South Korea
Gangnam Severance Hospital, Yonsei University Health System
Seoul, Seoul-teukbyeolsi [seoul], 06273, South Korea
Samsung Medical Center
Seoul, Seoul-teukbyeolsi [seoul], 06351, South Korea
The Catholic Univ. of Korea Seoul St. Mary's Hospital
Seoul, Seoul-teukbyeolsi [seoul], 06591, South Korea
Ewha Womans University Mokdong Hospital
Seoul, Seoul-teukbyeolsi [seoul], South Korea
CHUAC-Hospital Teresa Herrera
A Coruña, A Coruña [LA Coruña], 15006, Spain
Hospital General Universitario de Elche
Elche, Alicante, 03203, Spain
Institut Català d'Oncologia (ICO) - Badalona
Badalona, Barcelona [barcelona], 08916, Spain
Parc de Salut Mar - Hospital del Mar
Barcelona, Barcelona [barcelona], 08003, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [barcelona], 08035, Spain
Osi Bilbao-Basurto
Bilbao, Basque Country, 48013, Spain
Institut Català d'Oncologia - L'Hospitalet
L'Hospitalet de Llobregat, Catalunya [cataluña], 08908, Spain
Hospital Universitario Donostia
Donostia / San Sebastian, Gipuzkoa, 20014, Spain
Hospital Universitario Arnau de Vilanova de Lleida
Lleida, Lleida [lérida], 25198, Spain
Hospital Universitario 12 de Octubre
Madrid, Madrid, Comunidad de, 28041, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Málaga, 29010, Spain
Salut Sant Joan de Reus-Baix Camp (Edp)
Reus, Tarragona [tarragona], 43204, Spain
Hospital Universitario Virgen Nieves
Granada, 18012, Spain
Hospital Universitario San Cecilio
Granada, 18016, Spain
Hospital Universitario La Paz
Madrid, 28046, Spain
Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
Althaia, Xarxa Assistencial Universitària de Manresa
Manresa, 8423, Spain
Hospital Universitario Virgen Macarena
Seville, 41009, Spain
Hospital General Universitario de Valencia
Valencia, 46014, Spain
Södersjukhuset
Stockholm, Stockholms LÄN [se-01], 11883, Sweden
Tumor Zentrum Aarau
Aarau, Canton of Aargau, 5000, Switzerland
Kantonsspital Frauenfeld - Spital Thurgau AG
Frauenfeld, Thurgau, 8500, Switzerland
Kantonsspital Münsterlingen - Spital Thurgau AG
Münsterlingen, Thurgau, CH8596, Switzerland
Chang Gung Memorial Hospital at Kaohsiung
Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan
Chi Mei Medical Center
Tainan, Tainan, 71004, Taiwan
Chi Mei Hospital - Liouying Branch
Tainan, Tainan, 73657, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 80756, Taiwan
China Medical University Hospital
Taichung, 40447, Taiwan
National Cheng Kung University Hospital
Tainan, 704, Taiwan
National Taiwan University Hospital
Taipei, 10002, Taiwan
Mackay Memorial Hospital
Taipei, 10449, Taiwan
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
Koo Foundation Sun Yat-Sen Cancer Center
Taipei, 112, Taiwan
Taipei Municipal Wan Fang Hospital
Taipei, 116, Taiwan
Chang Gung Medical Foundation-Linkou Branch
Taoyuan District, 333, Taiwan
Hacettepe Universite Hastaneleri
Altindağ, Ankara, 06230, Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
Istanbul, İ̇stanbul, 34722, Turkey (Türkiye)
Acibadem Altunizade Hospital
Istanbul, İ̇stanbul, 34752, Turkey (Türkiye)
I.E.U. Medical Point Hastanesi
Izmir, İ̇zmir, 35575, Turkey (Türkiye)
Adana Medical Park Seyhan Hastanesi
Adana, 01140, Turkey (Türkiye)
Adana Sehir Egitim ve Arastirma Hastanesi
Adana, 01370, Turkey (Türkiye)
Gulhane Egitim Arastirma Hastanesi
Ankara, 06010, Turkey (Türkiye)
Memorial Ankara Hastanesi
Ankara, 06520, Turkey (Türkiye)
Ankara Bilkent Şehir Hastanesi
Ankara, 06800, Turkey (Türkiye)
Akdeniz Universitesi Hastanesi
Antalya, 07059, Turkey (Türkiye)
Trakya University Medical Faculty Hospital
Edirne, 22030, Turkey (Türkiye)
Samsun Medical Park Hastanesi
Samsun, 55200, Turkey (Türkiye)
St Bartholomew's Hospital
London, London, CITY of, EC1A 7BE, United Kingdom
Royal Blackburn Hospital
Blackburn, BB2 3HH, United Kingdom
The Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
The Christie Hospital NHS Foundation Trust
Manchester, M20 4GJ, United Kingdom
Related Publications (2)
Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, Zamagni C, Cui J, Cazzaniga M, Cil T, Jerzak KJ, Fuentes C, Yoshinami T, Rodriguez-Lescure A, Sezer A, Fontana A, Guarneri V, Molckovsky A, Mouret-Reynier MA, Demirci U, Zhang Y, Valota O, Lu DR, Martignoni M, Parameswaran J, Zhi X, Hamilton EP; VERITAC-2 Study Group. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. N Engl J Med. 2025 Aug 7;393(6):556-568. doi: 10.1056/NEJMoa2505725. Epub 2025 May 31.
PMID: 40454645DERIVEDHamilton EP, Ma C, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA, Danso M, Lu DR, Perkins Smith J, Liu Y, Tran L, Anderson S, Campone M. VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future Oncol. 2024;20(32):2447-2455. doi: 10.1080/14796694.2024.2377530. Epub 2024 Jul 29.
PMID: 39072356DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Pfizer ClinicalTrials.gov Call Center
- Organization
- Pfizer Inc.
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 16, 2022
First Posted
December 16, 2022
Study Start
March 3, 2023
Primary Completion
January 31, 2025
Study Completion (Estimated)
May 15, 2028
Last Updated
March 18, 2026
Results First Posted
February 3, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will share
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.